Latest Lead News

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

Argent Minerals has identified three extensive VTEM anomalies at its Kempfield NW Prospect, including two untested trends, signaling significant potential to expand its flagship silver-base metals deposit in New South Wales.

Firebird Metals has installed new equipment at its Chinese R&D lab, enabling complete lab-scale production from ore to lithium manganese iron phosphate cathode. This milestone supports a strategic collaboration with Central South University and promises cost advantages in battery material manufacturing.

Eclipse Metals has successfully raised $2 million through an oversubscribed placement at market price, aiming to accelerate exploration and environmental work at its Grønnedal rare earth project in Greenland.

Monash IVF has disclosed a significant embryo transfer error at its Clayton laboratory, prompting an internal investigation and expanded independent review. The company is implementing new safeguards while maintaining its profit outlook.

Renegade Exploration Limited reports impressive high-grade gold rock chip results from its newly acquired Caisson Project in Nevada’s Walker Lane Trend, highlighting strong exploration potential.

Syntara Limited’s lead drug candidate SNT-5505 has secured FDA Fast Track designation, expediting its development for treating myelofibrosis, a rare and serious blood cancer with limited therapies.

Coronado Global Resources has strengthened its financial position with a $150 million liquidity injection and a pivotal five-year coal supply agreement with Stanwell Corporation, reshaping its export potential from 2027.

Pure Foods Tasmania has raised $100,000 through a share placement and appointed directors to new operational roles aimed at driving sales growth and improving cost efficiency.

AnteoTech Ltd has completed a strategic review that refocuses its business on commercialising existing products, delivering $1.6 million in annual cost savings and expanding its sales pipeline in battery and life sciences markets.

Argenica Therapeutics faces a clinical hold from the US FDA on its stroke drug trial application, though its Australian Phase 2 study remains unaffected and on track.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.